Celgene Corporation (CELG) versus Its Peers Head-To-Head Survey

Celgene Corporation (NASDAQ: CELG) is one of 108 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Celgene Corporation to related businesses based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, analyst recommendations and risk.


This table compares Celgene Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celgene Corporation 27.36% 63.80% 17.45%
Celgene Corporation Competitors -2,661.53% -66.13% -9.54%

Earnings & Valuation

This table compares Celgene Corporation and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Celgene Corporation $11.23 billion $2.00 billion 24.31
Celgene Corporation Competitors $8.85 billion $1.19 billion 158.90

Celgene Corporation has higher revenue and earnings than its competitors. Celgene Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Celgene Corporation and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celgene Corporation 1 9 18 1 2.66
Celgene Corporation Competitors 842 3700 6655 185 2.54

Celgene Corporation presently has a consensus price target of $139.77, suggesting a potential upside of 36.57%. As a group, “Pharmaceuticals” companies have a potential upside of 24.76%. Given Celgene Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Celgene Corporation is more favorable than its competitors.

Volatility and Risk

Celgene Corporation has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Celgene Corporation’s competitors have a beta of 33.76, indicating that their average share price is 3,276% more volatile than the S&P 500.

Institutional and Insider Ownership

78.9% of Celgene Corporation shares are held by institutional investors. Comparatively, 43.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.0% of Celgene Corporation shares are held by company insiders. Comparatively, 11.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Celgene Corporation beats its competitors on 10 of the 13 factors compared.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply